CARLSBAD, Calif. , Nov. 13, 2024 /PRNewswire/ -- Tyra Biosciences, Inc.
(Nasdaq: TYRA ), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Jefferies London Healthcare Conference, November 19-21 st , 2024: Todd Harris , CEO of TYRA, will participate in a fireside chat on Tuesday, November 19th , at 2:00 pm GMT. TYRA management will also participate in one-on-one investor meetings and B2B meetings. 36 th Annual Piper Healthcare Conference, December 3-5 th , 2024, New York : Mr.
Harris will participate in a fireside chat on Wednesday, December 4 th , at 10:30 am ET . TYRA management will also participate in one-on-one meetings with investors. A live and archived webcast of the fireside chats will be available via the For Investors page on the TYRA website.
About Tyra Biosciences Tyra Biosciences, Inc. (Nasdaq: TYRA ) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies.
TYRA's expertise in FGFR biology has created a differenti.
